GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a...
Janssen to trial mosaic-based HIV-1 preventive vaccine
Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a maintenance therapy in the Phase III PRIMA clinical trial involving ovarian cancer patients.
Lilly’s Emgality shows favourable profile in Phase III studies
Eli Lilly has reported positive data from post-hoc analyses of three Phase III clinical trials, REGAIN, EVOLVE-1 and EVOLVE-2, of its migraine drug Emgality (galcanezumab-gnlm).
Dolutegravir plus lamivudine yields positive data in HIV study
ViiV Healthcare has reported that the Phase III TANGO clinical trial of dolutegravir plus lamivudine met the primary endpoint of controlling HIV-1 infection in virally suppressed patients.
Rimegepant shows positive result as migraine drug in Phase III trial
Biohaven Pharmaceutical has reported that a single dose of its rimegepant drug has led to pain freedom in a pivotal Phase III clinical trial involving migraine patients.
EIP Pharma trials neflamapimod to treat cognitive deficits
EIP Pharma has started a proof-of-concept Phase II clinical trial to assess its investigational drug neflamapimod for treating cognitive dysfunction caused by Huntington's disease.
Intra-Cellular reports mixed data from lumateperone studies
Intra-Cellular Therapies has announced top-line data from two Phase III clinical trials, study 401 and study 404, of its lumateperone as a monotherapy to treat major depressive episodes in bipolar I or bipolar II disorder patients.
Ipsen-Servier’s Onivyde shows favourable profile in study
Ipsen and Servier have reported initial findings obtained from an ongoing Phase I/II clinical trial of Onivyde (liposomal irinotecan injection) in previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) patients.
GSK launches Phase III programme of RA drug otilimab
GlaxoSmithKline (GSK) has initiated a Phase III clinical development programme of its investigational, rheumatoid arthritis (RA) drug otilimab.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.